Provided by Tiger Fintech (Singapore) Pte. Ltd.

Relmada Therapeutics, Inc.

0.2947
+0.00200.68%
Volume:282.08K
Turnover:81.32K
Market Cap:8.89M
PE:-0.10
High:0.2999
Open:0.2910
Low:0.2812
Close:0.2927
Loading ...

Relmada Therapeutics Inc: to Explore Strategic Alternatives

THOMSON REUTERS
·
09 Dec 2024

Press Release: Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dow Jones
·
09 Dec 2024

Relmada Shares Continue Downward Spiral After Downgrades

MT Newswires Live
·
06 Dec 2024

Mizuho Securities downgrades Relmada Therapeutics (RLMD) to a Hold

TIPRANKS
·
06 Dec 2024

Mizuho Downgrades Relmada Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $23

MT Newswires Live
·
05 Dec 2024

Relmada Therapeutics Inc : Mizuho Cuts to Neutral From Outperform

THOMSON REUTERS
·
05 Dec 2024

U.S. RESEARCH ROUNDUP- Autozone, Costco Wholesale, Salesforce

Reuters
·
05 Dec 2024

Relmada Therapeutics Inc : Leerink Partners Cuts Target Price to $1 From $10

THOMSON REUTERS
·
05 Dec 2024

Leerink Partners Downgrades Relmada Therapeutics to Market Perform From Outperform, $1 Price Target; Shares Plummet

MT Newswires Live
·
05 Dec 2024

Relmada Therapeutics Inc : Jefferies Cuts to Hold From Buy; Cuts Target Price to $0.60 From $13

THOMSON REUTERS
·
04 Dec 2024

Relmada Therapeutics Shares Down 76.5% After Analysis Shows Depression Drug Unlikely to Meet Main Goal

THOMSON REUTERS
·
04 Dec 2024

Relmada Study of Major-Depression Treatment Deemed Futile; Shares Plummet - Update

Dow Jones
·
04 Dec 2024

BUZZ-Relmada Therapeutics slumps as depression drug unlikely to meet main trial goal

Reuters
·
04 Dec 2024

Relmada Therapeutics Shares Resume Trading Premarket, Last Down 78.7% After Co's Depression Drug Unlikely to Meet Main Trial Goal

THOMSON REUTERS
·
04 Dec 2024

Relmada Therapeutics' Late-Stage Trial of REL-1017 Deemed 'Futile' -- Shares Decline Pre-Bell

MT Newswires Live
·
04 Dec 2024

Relmada Therapeutics Study of Major Depressive Disorder Treatment Assessed as Futile

Dow Jones
·
04 Dec 2024